Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2002

View Archived Issues

Potential use of efalizumab in the treatment of T-cell-mediated diseases

The ETA receptor antagonist BQ-123 prevents endothelial dysfunction induced by mental stress

Adjuvant QS-21 enhances immunogenicity of malaria peptide vaccine

Transkaryotic Therapies announces second quarter highlights

Alizyme offers six-month progress report

Neurodex enters phase II trial in diabetic neuropathic pain

Biopure submits Hemopure BLA

Xyotax enters phase II trial in breast cancer

Initiation of phase II/III trial of CEP-1347 in early-stage Parkinson's disease

MT-400 development program agreed with FDA and MCA

MTC-DOX designated orphan drug in E.U.

Novel glucokinase activators described in Roche patent

Merck Frosst presents caspase-3 inhibitors with potential in ischemic disorders

Novel topoisomerase I inhibitors in Advanced Life Sciences pipeline

Akzo Nobel researchers identify new androgenic/progestagenic compounds

Bayer claims novel beta3-adrenoceptor agonists for diabetes, obesity, etc.

New quinolones and quinolizinones in early development at P&G